Wyeth earnings
This article was originally published in The Tan Sheet
Executive Summary
Worldwide Consumer Healthcare net revenue was flat at $598 mil. during the second quarter, Wyeth announces July 20. Net revenue for the division worldwide during the first six months of 2006 decreased 5% to $1.16 bil. when compared to the first six months of 2005. An increase in sales of Advil and Centrum vitamins helped offset losses caused by lower sales of Robitussin, Dimetapp and Advil Cold & Sinus, which resulted from increased retailer restrictions on pseudoephedrine-containing products, the company says. The earnings also reflect the loss of Solgar vitamin sales; the brand was divested to NBTY in the third quarter of 2005 (1"The Tan Sheet" Jan. 16, 2006, p. 13). Wyeth Nutrition's second-quarter net revenue increased 13% over the prior-year period to $300 mil...
You may also be interested in...
Solgar Brand Leads First-Quarter NBTY Sales Growth
NBTY's recently-acquired Solgar vitamin brand continues to drive the firm's sales, the company reported in a first-quarter earnings statement Jan. 9
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.